Form 4: Aclaris Therapeutics Director Leonard Braden Michael Increases Stake in Company

Director Leonard Braden Michael reports acquiring additional shares of Aclaris Therapeutics, Inc. through BML Investment Partners, L.P.

Summary

• On June 27, 2024, Leonard Braden Michael, a director of Aclaris Therapeutics, Inc., acquired 235,000 shares of common stock at a weighted average price of $1.1546 per share.
• On June 28, 2024, he acquired 801,000 shares at a weighted average price of $1.1193 per share and an additional 400,000 shares at $1.13 per share.
• On July 1, 2024, he acquired 107,434 shares at a weighted average price of $1.1373 per share.
• These transactions increased his indirect holdings through BML Investment Partners, L.P. to 13,095,572 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but it's a routine filing.

Positives

• The director's increased investment could be interpreted as a positive signal about the company's prospects.

Industry Context

Director share purchases are often viewed as a sign of confidence in the company's future performance, which can influence investor sentiment.

Stakeholder Impact

• The increased shareholding by a director could positively influence shareholder confidence.

Key Dates